The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

CLL can mean fatigue, fear and years of waiting but new research shows that staying active helps people feel better – and ...

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

The FDA has loosened safety restrictions for six CAR T-cell immunotherapies, used in treating a number of blood cancers.

It is designed to treat lymphoblastic leukaemia and diffuse large B-cell lymphoma. India’s Kauvery Hospital has announced the launch of its CAR-T cell therapy service for certain blood cancers that do ...

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...

B-cell lymphoma study identifies traits tied to greatest benefit from CD19 CAR T cell therapy by Jade Waddy, University of Texas M. D. Anderson Cancer Center edited by Lisa Lock, reviewed by ...

Breyanzi was approved in 2024 to treat a type of non-Hodgkin lymphoma called large B-cell lymphoma (LBCL). Below you’ll find common questions and answers about Breyanzi to help decide whether it ...

Conclusions In summary, we present an interesting case of B-lymphoblastic leukemia with unusual surface light chain expression in a patient who has previously undergone myeloma treatment.

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence. Despite its rarity and the lack of recognition by the World Health Organization as a ...